Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00927914 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy
A Phase 2 study of Mild to Moderate Diabetic Sensorimotor Polyneuropathy, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 800
- Enrollment target
- 1
- Study location
NCT00927914: Completed Phase 2 study of Mild to Moderate Diabetic Sensorimotor Polyneuropathy, sponsored by Eisai.
NCT00927914 is a Phase 2 study of Mild to Moderate Diabetic Sensorimotor Polyneuropathy that has completed, run by Eisai. The registered enrollment target is 800 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (502% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00927914, a Phase 2 study of Mild to Moderate Diabetic Sensorimotor Polyneuropathy, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 800 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effect of 40 mg and 80 mg ranirestat on peroneal motor nerve conduction velocity relative to placebo in subjects with mild to moderate diabetic sensorimotor polyneuropathy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ranirestat
Study Locations (1)
Maryland
- The Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2009-07 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
What the finished NCT00927914 record still lists
NCT00927914 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (502% higher).
The record links to 1 condition, with Mild to Moderate Diabetic Sensorimotor Polyneuropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00927914 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00927914 about?
NCT00927914 is a clinical study titled "Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy". The purpose of this study is to determine the effect of 40 mg and 80 mg ranirestat on peroneal motor nerve conduction velocity relative to placebo in subjects with mild to moderate diabetic sensorimotor polyneuropathy.
What is the current status of trial NCT00927914?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 800 participants. The study started on 2009-07. Estimated completion is 2013-02.
What conditions does trial NCT00927914 study?
This clinical trial studies the following conditions: Mild to Moderate Diabetic Sensorimotor Polyneuropathy.
What interventions are being tested in trial NCT00927914?
The interventions under investigation include: Placebo (DRUG), Ranirestat (DRUG).
Who is sponsoring clinical trial NCT00927914?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00927914 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00927914's enrollment target sits among peer trials
800 37th of 2000 higher than 1,961 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia